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 Combined Carbon Dioxide Laser with Photodynamic Therapy for
Nodular and Superficial Basal Cell Carcinoma
Almost Scarless Cure With Minimal Recurrence
Kayvan Shokrollahi, BSc, MB, ChB, MSc, LLM, MRCS, FRCS(Plast),*Þ
Mohammed Javed, MB, ChB, MRCS,* Karen Aeuyung, MRCS,* Amar Ghattaura, FRCS(Plast),*
Iain S. Whitaker, MB, BChir, MA(Cantab), MRCS, FRCS(Plast), PhD,* Barbara O’Leary, RGN,*
William James, BSc,* and Maxwell Murison, FRCS(Plast)*
Background: Basal cell carcinomas (BCCs) are often seen by general prac-
titioners, plastic surgeons, and dermatologists in the outpatient setting. Pho-
todynamic therapy (PDT) and CO2 laser when used as monotherapy have been
successfully used to treat small BCC, with greatest success in the superficial
histological subtype but have limitations compared to surgical excision due to
a limited depth of penetration of PDT (2 mm absorption) limiting efficacy. We
describe our experience of dual-modality treatment improving efficacy, cos-
metic outcomes, and minimizing recurrence.
Methods: One hundred ten patients with a total of 177 lesions mainly on the
head and neck were treated with combined therapy using an UltraPulse CO2
laser and PDT using methyl aminolevulinate (METVIX) at the same sitting,
with repeat PDT 1 week later. We evaluated recurrences, cosmetic outcomes,
patient satisfaction, and costs.
Results: The mean age of patients was 67 years. The mean follow-up period
was 32.2 months, with a range of 7.7 to 68.5 months. Eighty six lesions were
followed up for more than 3 years. A total of 177 lesions were diagnosed and
treated. Only biopsy-proven BCCs were included in this study. Histologically,
34 (19.2%) were superficial subtype, 50 (28.2%) nodular, 9 (5.08%) infiltra-
tive, 7 (3.95%) morpheic, 3 (1.69%) mixed, and in 74 (41.8%) diagnosis was
simply BCC. All lesions responded to treatment as assessed by clinical evalu-
ation with regular follow-up. The total recurrence-free rate was 97.1%. In
88.1% lesions, a single cycle of treatment was required; 9.03% had 2 cycles and
0.56% underwent 3 cycles. In 3 of the patients, no data were available. Recur-
rences were noted in 5 (2.82%) cases. All recurrences were treated successfully,
all but one using repeat laser-PDT. One patient underwent surgical excision. No
significant complications were encountered, although mild hypopigmentation
was occasionally seen and some discomfort is experienced with PDT.
Conclusions: Combined CO2 laser and PDT have equivalent cure rates to
surgery for BCCsVnotably of the nodular subtypeVthese modalities acting
synergistically. This strategy provides cure often with scarless outcomes as il-
lustrated. Laser with PDT is most appropriate for patients who value excellent
cosmetic outcomes and where avoidance of an invasive procedure is an im-
portant factor. In addition, this modality comes into its own for specific groups
of patients, such as those on Warfarin or those with diffuse or multiple lesions.
Key Words: laser, CO2, PDT, photodynamic therapy, BCC, basal carcinoma,
MAL-PDT, ALA
(Ann Plast Surg 2013;70: 00Y00)
BACKGROUND
One of the difficulties in the management of basal cell carci-
noma (BCC) is rationalizing the concept of ‘‘a cancer that isn’t a
cancer.’’ Although these skin tumors are acknowledged as the leading
cause of cancer in the western world,1 both the medical profession
and the lay public consider the notion of ‘‘cancer’’ as a disease which
is commonly life-threatening and has the potential to metastasize. On
both these counts, BCCs invariably fail to fulfill the perceived defi-
nition, and this leads many clinicians to use alternative terminology
in discussions with patientsVsuch as ‘‘rodent ulcer’’Vto avoid the
use of the ‘‘c’’ word, which is unduly alarming and does not appro-
priately reflect the prognosis of most of these lesions. Although rare
reports do exist of metastasis, and some lesions that have been
neglected or are of certain histological subtypes in specific anatom-
ical locations can be aggressive and occasionally fatal, this scenario
is rare.2 The morbidity associated with BCCs is therefore more
commonly related to cosmetic deformity and functional compromise
related to treatment itselfVsuch as surgery including skin grafts and
local flaps, rather than to mortality. Unlike melanoma and squamous
carcinoma, the primary treatment for which is surgical excision,
BCCs are treated using a large number of modalities [topical treat-
ments, curettage, cryotherapy, radiotherapy, photodynamic therapy
(PDT), laser, and surgery] under the care of surgeons, dermatologists,
and clinical oncologists.3,4 Most of these modalities can be consid-
ered ‘‘curative’’ depending on one’s threshold for ‘‘cure’’ in recur-
rence rates of each modality, and each have their own pros and cons.
The treatment options, evidence base, and outcomes of these have
been published by the UK National Institute for Clinical Excellence
and reviewed in other key papers.5,6
The most important outcome variables in the treatment of
BCCs, therefore, are recurrence rates and cosmetic outcome. Because
of the slow rate of growth of these lesions, and the generally favor-
able prognosis, topical treatments are commonly used for small and
superficial lesions based on clinical diagnosis. This avoids the scar-
ring associated with surgery, usually resulting in successful treat-
ment, leaving surgery as the next alternative in case of recurrence or
nonresolution. More invasive modalities tend to be used for larger
lesions or those of an aggressive histological subtype.
Photodynamic therapy and CO2 laser have both been suc-
cessfully used as monotherapy to treat BCCs,7Y16 with greatest suc-
cess in the superficial histological subtype. These modalities when
used alone have a number of limitations when compared to surg-
ical excision, in particular the limited depth of penetration of PDT
(2 mm), which potentially limits the efficacy of treatment of thicker
BCCs such as those of the common nodular subtype. Isolated CO2
laser ablation is associated with dermal scarring. We have previ-
ously published our preliminary experience of combination therapy
using both modalities simultaneously to demonstrate the initial
safety and efficacy in 12 patients with up to 1 year of follow-up.17
Subsequent to this preliminary study, we introduced dual-modality
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therapy for BCCs into routine practice in our unit after approval by
the hospital trust as a recognized treatment. We now describe our
definitive experience in treating 177 lesions in a large series, some
extending beyond 5 years of follow-up. These patients were offered
laser-PDT or surgery based on current evidence and underwent in-
formed consent based on our preliminary published experience.
Exclusion criteria are listed as follows:
ulcerated lesions,
radio-recurrent lesions,
lesions abutting the ocular mucosa, and
lesions with squamous differentiation.
METHODS
Laser-PDT Technique
We use an UltraPulse CO2 Laser (Lumenis, UK) set at 150 mJ,
10 Hz, with a 2-mm collimated beam to vaporize the BCCs, while
maintaining a bloodless field with no eschar. The CO2 laser is unique
in its ability to provide pinpoint accuracy in surgical ablation to a
depth of 200Km per pass of the laser while providing a bloodless field
which is critical to the feasibility of subsequently undertaking PDT at
the same sitting. This is also an advantage when treating patients on
aspirin or warfarin. The first pass of the laser ablates a 3-mm rim of
normal epidermis around the tumor to facilitate penetration of the
methyl aminolevulinate into tumor not visible on the surface.
Photodynamic therapy was carried out by application of the
photosensitizing agent methyl aminolevulinate (METVIX) [Galderma]
covered with an occlusive dressing for 3 hours and then typically
illuminated with the Aktilite 16 LED lamp at 631 nm, 37 J/cm2 for
7 minutes 24 seconds. Photodynamic therapy was alternatively ac-
tivated using Intense Pulsed Light (IPL)V(Energist Ultra Variable
Pulsed Light System; Energist, Swansea, UK) 80 J cmj2, double
pulsed at 40 J cmj2, pulse train of 15 impulses each with a duration
of 5 milliseconds using a 610 to 950-nm filtered hand piece. A dress-
ing with topical neomycin ointment (Polyfax), to continue for 5 days
is applied. Photodynamic therapy is repeated as per manufacturer’s
instructions 1 week later for all patients. Follow-up is undertaken at
6 weeks, 3 months, and 6 months, but often ongoing with patients
with numerous lesions and elastotic skin. Figure 1 illustrates the
treatment algorithm for laser-PDT. Of note, 3 of 5 patients with
recurrence refused surgery and opted for repeat laser-PDT in-
stead of surgery despite this algorithm. We include a table of basic
costs (Fig. 2).
No accurate record-keeping of size of lesions was available
that would have strengthened our study.
We also noted any poor cosmetic outcomes due to hypo-
pigmentation, which is a rare but recognized feature of PDT, as well
as any other notable problems. To assess for recurrence at follow-up,
the treated areas were compared with pretreatment and any previous
posttreatment photographs. The areas were then assessed clinically
for changes in size, shape, pigmentation, or for any evidence of tel-
angiectasia, ulceration, or nodularity.
In practical terms, the advantage of combination therapy lies in
the vaporization of the elevated nodular component of the BCC, to
produce a bloodless field at epidermal level, which is ready for ap-
plication of the photosensitizer. With removal of this raised compo-
nent, the depth of penetration of the PDT is likely to be enhanced,
potentially allowing greater efficacy of treatment.
Overall, the tolerance of the procedure was excellent. Mild
discomfort is a feature of PDT for any nature, and we have initially
overcome this with the use of electric fans, local anesthesia, water
sprays, ‘‘Jellyperm’’ pads, and diversion techniques during treatment.
A long-acting local anesthetic for the CO2 laser ablation part of the
procedure will still be effective at the time of PDT activation, and has
now all but eliminated the painful component of PDT activation.
Bupivacaine with epinephrine is a good choice which lasts long and
maintains an optimum bloodless field.
RESULTS
Response and Recurrence Rates
Of the 110 patients, 37 patients were men and 73 women. The
mean age was 67 years. The mean follow-up period was 32.2 months,
FIGURE 1. Treatment algorithm for laser-PDT.
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with a range of 7.7 to 68.5 months. Eighty-six lesions were followed
up for more than 3 years. A total of 177 lesions were diagnosed and
treated. Only biopsy-proven BCCs were included in this study.
Histologically, 34 (19.2%) lesions were superficial subtype, 50
(28.2%) nodular, 9 (5.08%) infiltrative, 7 (3.95%) morpheic, 3
(1.69%) mixed, and in 74 (41.8%) diagnosis was simply BCC. All
lesions responded to treatment as assessed by clinical evaluation
with regular follow-up. The total recurrence-free rate was 97.1%. In
88.1% lesions, a single cycle of treatment was required; 9.03% had
2 cycles and 0.56% underwent 3 cycles. In 3 of the patients, no data
were available. Recurrences were noted in 5 (2.82%) cases. All
recurrences but one were treated using repeat laser-PDT, 1 patient
underwent surgical excision. No significant complications were
encountered, although mild hypopigmentation was occasionally seen
in less than 5% of patients. Of the morpheic subtype of lesion, 2 of
7 recurred.
Patient-Related Outcomes
We were interested to compare laser-PDT with surgical treat-
ment from a patient perspective and as an audit tool to improve our
FIGURE 2. Basic (non-infrastructural) costings and materials for laser + PDT treatment of 1 lesion.
TABLE 1. Patient Satisfaction Questionnaire
1. How important was it for you to be treated quickly after your diagnosis of
skin cancer?
2. How would you rate the waiting time for treatment with (a) Surgery (b)
Laser?
3. How would you rate the anxiety caused with (a) Surgery (b) Laser?
4. Rate the pain of each treatment (a) Surgery (b) Laser.
5. Rate the scar left by each treatment (a) Surgery (b) Laser.
6. How disruptive was each treatment to your life (a) Surgery (b) Laser?
7. Can you rate your overall experience of treatment (a) Surgery (b) Laser?
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practice. Thirty-three patients were found to have had previous ex-
cisional surgery for BCCs. A 7-part audit questionnaire was designed
(Table 1) to compare the patients’ experience of surgery with laser-
PDT, answers all being on an analog scale of 0 to 10 (Figs. 3Y7).
Patients were all contacted by telephone and asked to complete the
questionnaire verbally with 20 responses. Statistical analysis of
results was performed using SPSS v15.0. A paired t test was used to
compare results from the patient satisfaction part of the study, with
confidence intervals set to 95%.
Patients preferred laser-PDT in all aspects except the pain
from treatment which was worse with PDT activation (and has been
subsequently resolved because of this audit). Our results were sta-
tistically highly significant in 2 specific areas despite the relatively
small numbers, these being the cosmetic outcome of the scar (P G
0.001) and the anxiety related to treatment (P G 0.001) (Table 2), as
well as the overall procedure. Further significant results included the
waiting time and pain of the procedure.
No other evidence has been published to date with refer-
ence to the anxiety caused by PDT or the other accepted treatment
modalities. The reason for patients being less anxious about PDT
were unclear but could possibly be related to the absence of an op-
erating room environment and the general factors associated with
surgery such as bleeding, diathermy (sound and smell), and lying flat
on an operating table. The pain experienced during treatment with
PDT is a recognized drawback of the treatment. This small audit
helped us to develop a long-acting local anesthesia strategy at the
time of CO2 ablation, eliminating the severe pain component of PDT.
DISCUSSION
Of all the numerous modalities that exist for the treatment of
BCC, only surgery (standard surgery and Mohs micrographic sur-
gery) provide histological confirmation of successful treatment. The
basis for treatment of BCCs with the other commonly used modali-
ties (cryotherapy, radiotherapy, topical therapies, curettage, PDT as
monotherapy, and laser monotherapy) rely on the evidence base for
successful treatment and recurrence rates. This study provides an
evidence base for laser-PDTwith 100% initial ablative response and
recurrence rates of 2.7% with an average of 32 months follow-up.
FIGURE 3. Patient-reported outcome surgery versus
laser-PDTVanxiety levels.
FIGURE 4 . Patient-reported outcome surgery versus
laser-PDTVpain scores.
FIGURE 5 . Patient-reported outcome surgery versus
laser-PDTVcosmetic outcome/scar.
FIGURE 6. Patient-reported outcome surgery versus
laser-PDTVdisruption to life.
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Our dual-therapy approach demonstrates synergism between the laser
and PDT, probably by a much greater penetration of PDT in the ab-
sence of epidermis and after subtotal lesional ablation. This may
extend the remit of these modalities to the treatment of larger le-
sions than were previously considered untreatable using laser or
PDT alone. This large series, many with more than 5 years follow-up,
provides a considerable weight of evidence to recommend this mo-
dality for oncological safety. As demonstrated in the figures, cos-
metic outcomes are exceptional, usually without a visible scar, and
laser-PDT is thus suited in particular for cosmetically sensitive areas
or for patients for whom surgery is a less favorable option. Examples
of patients having undergone treatment are illustrated in Figures
8Y11, and these images are typical rather than exemplary. These
dramatic results should provide incentive for future randomized
clinical controlled trials. The advantages of laser-PDT can be seen
when comparing the 2 different patients with almost identical lesions
in Figure 11: one patient treated with laser-PDT and the other with
flap reconstruction.
CO2 laser monotherapy is a very versatile device in skin on-
cological practice, providing good visualization of a bloodless plane,
short healing times, and excellent cosmetic outcomes.8Y10 UltraPulse
techniques, as used in this study, reduce unwanted thermal damage
extending outward from the ablation zone, thus improving healing
and reducing scarring.
Photodynamic therapy as monotherapy for BCCs is effec
tive in the treatment of BCCs with a better cosmetic result than
conventional surgery. However, there is a trend for higher recur-
rence rates with this modality in all but superficial subtypes due to a
limited depth of penetration.7,8,13 Photodynamic therapy as mono-
therapy for nodular BCCs has therefore fallen out of favor. This
evidence from large series of BCCs treated with PDT show a wide
range of response rates from 34% to 100%, with inferior clearance
rates in nodular compared with superficial subtypes. Methyl ami-
nolevulinate (METVIX) PDT is proven for BCC, offering advan-
tages over nonmethylated 5-ALA in improved skin penetration, and
routine use of double PDT treatments (as used in our protocol) is
recommended to improve treatment efficacy.18
This apparently synergistic treatment seems most appropriate
for patients who value excellent cosmetic outcome over the incon-
venience of making additional visits to the clinic, or where avoidance
of an invasive procedure is an important factor. We would advocate
this therapy following detailed consent from the patient (at which
point we discuss our own recurrence rates). It is appropriate to treat
lesions in certain anatomical areas, and those patients adverse to
surgical intervention by their own choice or as advised by their
clinician.
FIGURE 7. Patient-reported outcome surgery versus
laser-PDTVoverall experience.
TABLE 2. Patient-Related Outcome Data
Paired Differences
CI of Difference
Mean SD SE of Mean Lower Upper t df Significance
Waiting times 0.95 1.5 0.336 0.25 1.65 2.83 19 0.11
Anxiety 1.55 1.54 0.344 0.83 2.27 4.51 19 0.001
Pain j2.4 3 0.67 j3.8 0.997 j3.58 19 0.002
Scar outcome 2.15 1.57 0.35 1.42 2.88 6.15 19 0.001
Disruption j0.55 1.73 0.387 1.36 0.26 j1.42 19 0.172
Overall 1.65 1.34 0.302 1.02 2.28 5.47 19 0.001
CI indicates confidence interval; df, degrees of freedom (n j 1).
FIGURE 8. Large nodular lower eyelid BCC treated with
1 cycle of laser-PDT with outcome at 12 months.
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Photodynamic therapy and CO2 laser treatments, in either
single or multiple sessions, may or may not be cost effective de-
pending on patient factors and individual unit facilities. For ex-
ample, avoidance of admission of patients on warfarin for critical
reasons to the ward for anticoagulation and multiple coagulation
screens as a prelude to subsequent surgery would make laser-PDT a
more favorable strategy. A table of costs is provided. However, com-
bined laser-PDT may not be cost effective in all patients groups. Al-
though 5-methyl-ALA remains relatively expensive, further studies
with more cost-effective cheaper photoactivators may affect the cost
effectiveness of dual-modality therapy. Nevertheless, the costs remain
favorable compared to surgery.
In a modest audit of patient-related outcome measures and
satisfaction, laser-PDT scored highly and was preferred to surgery in
most measures. Patients found PDT-activation painful, which is a
recognized problem with PDT, and we substituted a long-acting local
anesthesia at the time of CO2 ablation which has mitigated this
problem.
We provide the clearest evidence so far that PDT and CO2
laser act synergistically in the treatment of BCC, and in particular
nodular BCC, setting the stage for future randomized clinical con-
trolled trials comparing surgery with laser-PDT. We have demonstrated
a safety track-record spanning 8 years with excellent clinical and
cosmetic outcomes.
CONCLUSIONS
We suggest that combining CO2 laser with PDT is an emerg-
ing frontline treatment for superficial and nodular BCCs, with min-
imal recurrence rates (G3%) and excellent cosmetic outcomes with
medium and long-term follow-up of up to 8 years.
Morpheic lesions should not be treated with this modality as
they have higher recurrence rates. CO2 laser and PDT seem to play a
synergistic role in the treatment of BCCs, and combined treatment
has extended the remit of PDT to allow treatment of larger and
nodular lesions, with the CO2 laser being unique as an accurate,
finely controlled and hemostatic ablative tool providing a wound bed
receptive to PDT. Both the surgical team and the patients have been
pleased with the results over many years. This treatment seems most
appropriate for patients who value excellent cosmetic outcomes over
the inconvenience of making additional visits to the clinic, or where
avoidance of an invasive procedure is an important factor. It is of
FIGURE 9. Young patient with nodular BCCVideal candidate
for this modality of treatment. Shown pretreatment and at
1 year.
FIGURE 10. A, B, C, Large nasal nodular BCC, (a) pretreatment and (b) at 2 years and (c) at 4 years after 2 treatment cycles.
FIGURE 11. Large nasal BCC pretreatment and at 1 year
posttreatment and comparison with equivalent lesion a
different patient treated with excision and flap reconstruction.
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potential benefit especially in cosmetically sensitive areas such as the
face, areas prone to poor scarring such as the presternal area, in
younger patients seeking excellent cosmesis, in patients for whom
anesthesia may be problematic, in patients with numerous and fre-
quently occurring lesions, or those taking anticoagulants (which do
not need cessation, nor the patients hospital admission). This treat-
ment modality complements surgery, not replaces it, in the arma-
mentarium of a holistic surgeon or physician treating cutaneous
malignancies and aiming for a scarless cure.
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